Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Qualitative, Cross-sectional Observational Study Exploring the Experience of Patients Prescribed Venetoclax+Rituximab or Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in Clinical Practice in the UK

NCT05555979 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05555979
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05555979 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Qualitative, Cross-sectional Observational Study Exploring the Experience of Patients Prescribed Venetoclax+Rituximab or Bruton's Tyrosine Kinase Inhibitors for Chronic Lymphocytic Leukaemia in Clinical Practice in the UK
Lead sponsor
AbbVie
Phase
Observational
Overall status
Completed
Start date
December 14, 2022
Completion date
April 10, 2024
Enrollment
56 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia